Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
about
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureHistone acetylation: novel target for the treatment of acute lymphoblastic leukemiaRegulation of Bim in Health and DiseaseThe BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsMulti-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemiaVenetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cellsBronchial epithelial cells are rendered insensitive to glucocorticoid transactivation by transforming growth factor-β1.Cancer epigenetics: a brief review.Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemiaThe biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.Novel agents for the treatment of childhood acute leukemia.p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.mTOR complex 2 signaling and functionsThe ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skinBcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsGlucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia.A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesEpigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Clofarabine in pediatric acute leukemia: current findings and issues.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Epigenetic modifications in pediatric acute lymphoblastic leukemia.
P2860
Q26746934-0450BEA5-C034-43A6-9D4C-B739142E14B1Q26778780-D05A3181-B96B-4C4C-92A6-D47E29F6A2A3Q26781203-DAA6860D-64BA-43D8-A0A2-FB0F99228E9CQ27010154-ADC03736-720C-46C9-BFF9-78DCE5D29C27Q28541556-F298406E-19E4-419F-A7AB-83ED39172894Q33433407-5159339C-08E8-47DF-8B2F-41DAD62C00DDQ33559964-A44505A2-40E6-48E1-B997-CF68C5976AE3Q33613763-D13A6863-4A95-4283-A44A-5047166FCE4BQ33614190-295C137A-FEAA-4752-9303-2CC63B12AADAQ33946996-35DC7148-9A28-41DD-BE0A-89B1CD0A7C8AQ33983255-582CDCDE-F0A0-4431-AB10-3441D656CC4CQ34026481-A9001C15-6920-4BAC-8ADA-E231A460D370Q34052660-E0F9AC87-41B7-4423-9D49-9FA99557E7F1Q34071295-F8E7D1A5-1AD4-478C-AA10-4B79C12E4BA0Q34091302-4E6B0780-4E4B-47D4-889A-C6A68553C372Q34173253-038C769F-41CC-4A36-B737-5CC491952D54Q34199935-8281FA94-F779-46AA-AED2-61D2E6C1C550Q34221738-B2317F55-0F0E-4C65-AE29-3AB50730050FQ34448969-E464A060-4084-4B52-A3C8-BF8E960F5E98Q34687627-C9B4B2BD-7AFB-4251-B72C-BE792AC350D7Q35192790-FDDDF5C0-D6A9-4664-9A03-F8D078567C17Q35423966-5A36CF93-940C-4DCA-8F08-99A868B922B3Q35553581-2E86976A-264D-4078-87C2-9F4B48616000Q35588268-9AD3325E-B19B-44A0-BC40-D3E45463E117Q35740019-36622D53-78CD-4888-9001-43DA6B8BDEF4Q35834635-6C45A348-F02A-4B01-86D7-B3F09B18CA03Q35878519-22447A34-A4ED-4E27-8B5D-A03A99C982FFQ35966223-01DFA068-6FE8-4B39-A63D-6A40592FABD6Q36057611-3515F4E1-9553-4705-BDED-C3FD1880ADF2Q36211482-2C41952A-3227-4395-8562-1763F2321148Q36225879-2E8B8F6A-9E5F-4A01-9578-9F0CE2856ADBQ36229432-66E0A4F7-4E85-4687-B897-BC6F339EEC14Q36438027-2667FFE0-A55E-4F3F-9094-DDA62E163D40Q36602853-0164C146-DC67-4064-8402-EB6961265076Q36801093-5FE7C393-6BB3-41B4-8615-B3E1F4F98047Q37629537-E561830C-5B81-4215-8CD1-5C0A1C0B8607Q37865381-721968BD-E20F-45D4-80E9-C620DFEBC5A8Q37987061-4E8632A9-84BF-4A9C-8225-896336E815C4Q38097334-0A74B0CC-4450-4C90-A585-38F6F44CE95DQ38214773-08246256-5FF9-4487-8DEF-05E64DB3538E
P2860
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Epigenetic silencing of BIM in ...... istone deacetylase inhibition.
@en
Epigenetic silencing of BIM in ...... istone deacetylase inhibition.
@nl
type
label
Epigenetic silencing of BIM in ...... istone deacetylase inhibition.
@en
Epigenetic silencing of BIM in ...... istone deacetylase inhibition.
@nl
prefLabel
Epigenetic silencing of BIM in ...... istone deacetylase inhibition.
@en
Epigenetic silencing of BIM in ...... istone deacetylase inhibition.
@nl
P2093
P50
P1433
P1476
Epigenetic silencing of BIM in ...... histone deacetylase inhibition
@en
P2093
Andrea Biondi
Angela Mogavero
Barbara Szymanska
Carwyn Davies
Diego Miranda-Saavedra
Giovanni Cazzaniga
Glenn M Marshall
Greta Geninson
John E Pimanda
Mary E Janes
P304
P356
10.1182/BLOOD-2010-05-284968
P407
P50
P577
2010-07-20T00:00:00Z